Emergency Nurses Association Names PDL Biopharma(R) as a 2007 Strategic Partner

Jun 13, 2007, 01:00 ET from Emergency Nurses Association

    CHICAGO, June 13 /PRNewswire/ -- The Emergency Nurses Association (ENA)
 today announced that PDL BioPharma(R) had been named a strategic partner
 for 2007. As a strategic partner, PDL BioPharma(R) will be the exclusive
 sponsor for the ENA State Leaders December Orientation and the Emergency
 Nurses Week, October 7-13, 2007.
     "We are very pleased to announce this partnership with PDL
 BioPharma(R)," said Donna Mason, RN, MS, CEN, ENA President. "By partnering
 with ENA, PDL BioPharma(R) gets a unique opportunity to show their support
 of the life saving work of emergency nurses across the county."
     Through this partnership, PDL BioPharma(R) will help finance ongoing
 educational opportunities, professional networking activities as well as
 events honoring nurses during emergency nurses week.
     "As a leader in the discovery, development and manufacturing of
 innovative therapies for serious or life-threatening illnesses, PDL
 BioPharma(R) has great respect for the work done by nurses in emergency
 departments every day," said Jaisim Shah, senior vice president, marketing
 and business affairs, PDL BioPharma Inc.
     "Like our ground breaking drugs for short-term hypertension treatment
 and acute myocardial infarction, these healthcare professionals are saving
 lives everyday. Through this partnership, we hope to raise the visibility
 of emergency nurses while showing our appreciation for everything that they
     In the United States and Canada, PDL BioPharma(R) markets several
 commercial biopharmaceutical products for the hospital setting --
 Cardene(R) I.V. (http://www.pdlbiopharma.com/index.cfm?navid=32) for the
 short-term treatment of hypertension, Retavase(R)
 (http://www.pdlbiopharma.com/index.cfm?navid=35) for acute myocardial
 infarction and IV Busulfex(R)
 (http://www.pdlbiopharma.com/index.cfm?navid=37) (Black Box Warning
 http://www.pdlbiopharma.com/index.cfm?navid=142) for conditioning prior to
 a bone marrow transplant in association with chronic myelogenous leukemia.
     About the Emergency Nurses Association
     The Emergency Nurses Association (ENA) is the only professional nursing
 association dedicated to defining the future of emergency nursing and
 emergency care through advocacy, expertise, innovation, and leadership.
 Founded in 1970, ENA serves as the voice of more than 32,000 members and
 their patients through research, publications, professional development,
 injury prevention, and patient education. Additional information is
 available at ENA's Web site, at http://www.ena.org.
     About PDL BioPharma(R)
     PDL BioPharma(R), Inc. is a biopharmaceutical company focused on
 discovering, developing and commercializing innovative therapies for severe
 or life-threatening illnesses. Commercially focused in the acute-care
 hospital setting, PDL markets and sells its portfolio of products in the
 United States and Canada. A pioneer of antibody humanization technology,
 PDL promotes this technology through licensing agreements and clinical
 development of its own diverse pipeline of investigational compounds. PDL's
 research platform centers on the discovery and development of antibodies to
 treat cancer and autoimmune diseases. For more information, please visit

SOURCE Emergency Nurses Association